Pyxis Oncology (PYXS) Change in Cash (2020 - 2025)
Pyxis Oncology (PYXS) posted quarterly Change in Cash of $6.5 million for Q4 2025, down 12.32% year-over-year from $7.4 million in Q4 2024, and up 458.49% quarter-over-quarter from -$1.8 million in Q3 2025.
Pyxis Oncology (PYXS) Change in Cash (2020 - 2025) Analysis & Trends
Pyxis Oncology (PYXS) has reported Change in Cash for 6 consecutive years, with $6.5 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Change in Cash fell 12.32% year-over-year to $6.5 million; the TTM figure through Dec 2025 stood at -$4.1 million (down 141.3% YoY), while the FY2025 annual figure was -$4.1 million, down 141.3% from the prior year.
- Change in Cash advanced to $6.5 million in Q4 2025 per PYXS's latest filing, from -$1.8 million in the prior quarter.
- Across five years, Change in Cash topped out at $142.7 million in Q4 2021 and bottomed at -$126.2 million in Q1 2023.
- Historically, Change in Cash has averaged $435300.0 across 5 years, with a median of -$5.9 million in 2023.
- Annual changes were most pronounced in 2021 — Change in Cash surged 4608.24% — and 2022, when it slumped 1417.86%.
- Pyxis Oncology's Change in Cash stood at $142.7 million in 2021, then slumped by 113.48% to -$19.2 million in 2022, then jumped by 73.75% to -$5.1 million in 2023, then surged by 246.84% to $7.4 million in 2024, then decreased by 12.32% to $6.5 million in 2025.
- Business Quant data shows PYXS's Change in Cash at $6.5 million in Q4 2025, -$1.8 million in Q3 2025, and -$2.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 649.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.60 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -185.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 427.25 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -2.94 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.42 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Pyxis Oncology | 198.37 Mn | 165.38 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 6.50 Mn |
| Sep 30, 2025 | -1.81 Mn |
| Jun 30, 2025 | -2.03 Mn |
| Mar 31, 2025 | -6.71 Mn |
| Dec 31, 2024 | 7.42 Mn |
| Sep 30, 2024 | -13.02 Mn |
| Jun 30, 2024 | -2.89 Mn |
| Mar 31, 2024 | 18.30 Mn |
| Dec 31, 2023 | -5.05 Mn |
| Sep 30, 2023 | -11.18 Mn |
| Jun 30, 2023 | -27.16 Mn |
| Mar 31, 2023 | -126.23 Mn |
| Dec 31, 2022 | -19.25 Mn |
| Sep 30, 2022 | -24.82 Mn |
| Jun 30, 2022 | -23.84 Mn |
| Mar 31, 2022 | -27.65 Mn |
| Dec 31, 2021 | 142.73 Mn |
| Sep 30, 2021 | -9.00 Mn |
| Jun 30, 2021 | 1.81 Mn |
| Mar 31, 2021 | 132.58 Mn |